...
首页> 外文期刊>British journal of anaesthesia >Dialysability of sugammadex and its complex with rocuronium in intensive care patients with severe renal impairment
【24h】

Dialysability of sugammadex and its complex with rocuronium in intensive care patients with severe renal impairment

机译:Sugammadex及其复合物与罗库溴铵在严重肾功能不全的重症监护患者中的可透析性

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background. Renal excretion is the primary route for the elimination of sugammadex. We evaluated the dialysability of sugammadex and the sugammadexrocuronium complex in patients with severe renal impairment in the intensive care unit (ICU). Methods. Six patients in the ICU with acute severe renal impairment received general anaesthesia for transoesophageal echocardiography, to replace their tracheal tubes, or for bronchoscopy. Five of the six patients were in the ICU after cardiac/vascular surgery and one for pneumonia-induced respiratory failure. They all received rocuronium 0.6 mg kg -1, followed 15 min later by sugammadex 4.0 mg kg -1. Two patients were studied for two dialysis episodes and four patients for four episodes. Rocuronium and sugammadex concentrations were measured in plasma and dialysate at several time points before, during, and after high-flux dialysis. Dialysis clearance in plasma and dialysate, and reduction ratio (RR) (the extent of the plasma concentration reduction at the end of a dialysis episode when compared with before dialysis) were calculated for each dialysis episode. Results. Dialysis episodes lasted on average 6 h. Observed RRs indicated mean reductions of 69% and 75% in the plasma concentrations of sugammadex and rocuronium, respectively, during the first dialysis episode. Reductions were around 50% during sequential dialysis episodes. On average, dialysis clearance of sugammadex and rocuronium in blood was 78 and 89 ml min -1, respectively. Conclusions. Haemodialysis using a high-flux dialysis method is effective in removing sugammadex and the sugammadexrocuronium complex in patients with severe renal impairment.
机译:背景。肾脏排泄是消除sugammadex的主要途径。我们评估了重症监护病房(ICU)中严重肾功能不全患者的sugammadex和sugammadexrocuronium复合物的透析性。方法。 ICU中有6例严重急性肾功能不全的患者接受了全麻麻醉,以经食管超声心动图检查,更换其气管导管或进行支气管镜检查。 6例患者中有5例在心脏/血管手术后进入ICU,1例因肺炎引起的呼吸衰竭。他们都接受了罗库溴铵0.6 mg kg -1,然后在15分钟后接受了舒玛葡糖4.0 mg kg -1。对两名患者进行了两次透析治疗,对四名患者进行了四次透析治疗。在高通量透析之前,过程中和之后的几个时间点,在血浆和透析液中测量罗库溴铵和sugammadex的浓度。计算每个透析发作的血浆和透析液中的透析清除率和还原率(RR)(透析发作结束时与透析前相比血浆浓度降低的程度)。结果。透析发作平均持续6 h。观察到的RRs表明,在第一次透析期间,sugammadex和罗库溴铵的血浆浓度分别平均降低了69%和75%。在顺序透析期间,减少约50%。平均而言,血液中的舒马得克斯和罗库溴铵的透析清除率分别为78和89 ml min -1。结论。使用高通量透析方法的血液透析可有效去除严重肾功能不全患者的sugammadex和sugammadexrocuronium复合物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号